Skip to main content

Evoclin

Generic name: clindamycin phosphate
Treatment for: Acne

Connetics' New Drug Application for Actiza Has Been Accepted For Filing by the FDA

PALO ALTO, Calif., March 4, 2004 -- Connetics Corporation (Nasdaq: CNCT), a specialty pharmaceutical company focused on dermatology, today announced that it has received confirmation that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Actiza, as of December 24, 2003. Actiza is an investigational new drug formulation of 1% clindamycin delivered in the Company's proprietary VersaFoam(TM) delivery system, as a potential new topical treatment for acne.

About Connetics
Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. The Company's marketed products are OLUX (clobetasol propionate) Foam, 0.05% and Luxiq (betamethasone valerate) Foam, 0.12%. Connetics is developing Extina, a foam formulation of the antifungal drug ketoconazole, Actiza, a foam formulation of clindamycin for treating acne, and Velac Gel, a combination of clindamycin and tretinoin for treating acne. Connetics has branded its innovative foam drug delivery vehicle VersaFoam(TM). These formulations aim to improve the management of dermatological diseases and provide significant product differentiation, and have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit www.connetics.com

Source: Connetics Corporation

Posted: March 2004

Related articles

Evoclin (clindamycin phosphate) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.